Home › Research › Mild cognitive impairment
Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage
Drago V, Babiloni C, Bartrés-Faz D, Caroli A, Bosch B, Hensch T, Didic M, Klafki HW et al.. Journal of Alzheimer's disease : JAD, 2011-01-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Older persons with Mild Cognitive Impairment (MCI) feature neurobiological Alzheimer's Disease (AD) in 50% to 70% of the cases and develop dementia within the next 5 to 7 years. Current evidence suggests that biochemical, neuroimaging, electrophysiological, and neuropsychological markers can track the disease over time since the MCI stage (also called prodromal AD). The amount of evidence supporting their validity is of variable strength. We have reviewed the current literature and categorized evidence of validity into three classes: Class A, availability of multiple serial studies; Class B a single serial study or multiple cross sectional studies of patients with increasing disease severity from MCI to probable AD; and class C, multiple cross sectional studies of patients in the dementia stage, not including the MCI stage. Several Class A studies suggest that episodic memory and semantic fluency are the most reliable neuropsychological markers of progression. Hippocampal atrophy, ventricular volume and whole brain atrophy are structural MRI markers with class A evidence. Resting-state fMRI and connectivity, and diffusion MR markers in the medial temporal white matter (parahippocampus and posterior cingulum) and hippocampus are promising but require further validation. Change in amyloid load in MCI patients warrant further investigations, e.g. over longer period of time, to assess its value as marker of disease progression. Several spectral markers of resting state EEG rhythms that might reflect neurodegenerative processes in the prodromal stage of AD (EEG power density, functional coupling, spectral coherence, and synchronization) suffer from lack of appropriately designed studies. Although serial studies on late event-related potentials (ERPs) in healthy elders or MCI patients are inconclusive, others tracking disease progression and effects of cholinesterase inhibiting drugs in AD, and cross-sectional including MCI or predicting development of AD offer preliminary evidence of validity as a marker of disease progression from the MCI stage. CSF Markers, such as Aβ 1-42, t-tau and p-tau are valuable markers which support the clinical diagnosis of Alzheimer's disease. However, these markers are not sensitive to disease progression and cannot be used to monitor the severity of Alzheimer's disease. For Isoprostane F2 some evidence exists that its increase correlates with the progression and the severity of AD.
What this study adds
Evidence grade: Low
This is a cross-sectional study. This review found that episodic memory and semantic fluency are the most reliable neuropsychological markers of progression from mild cognitive impairment to Alzheimer's disease, and that hippocampal atrophy and whole brain atrophy have strong evidence as structural markers. The findings are about tracking disease progression and do not report on treating, curing, or preventing Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Drago, V., Babiloni, C., Bartrés-Faz, D., Caroli, A., Bosch, B., Hensch, T., et al. (2011). Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage. Journal of Alzheimer's disease : JAD. https://doi.org/10.3233/jad-2011-0043
Vancouver
Drago V, Babiloni C, Bartrés-Faz D, Caroli A, Bosch B, Hensch T, et al. Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage. Journal of Alzheimer's disease : JAD. 2011. doi:10.3233/jad-2011-0043. PMID: 21971460.
BibTeX
@article{drago2011-21971460,
author = {Drago, V. and Babiloni, C. and Bartrés-Faz, D. and Caroli, A. and Bosch, B. and Hensch, T. and Didic, M. and Klafki, H. W. and others},
title = {{Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage}},
journal = {Journal of Alzheimer's disease : JAD},
year = {2011},
doi = {10.3233/jad-2011-0043},
pmid = {21971460},
url = {https://doi.org/10.3233/jad-2011-0043}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Current evidence suggests that biochemical, neuroimaging, electrophysiological, and neuropsychological markers can track the disease over time since the MCI stage (also called prodromal AD).
- Several Class A studies suggest that episodic memory and semantic fluency are the most reliable neuropsychological markers of progression.
Why it matters
This review found that episodic memory and semantic fluency are the most reliable neuropsychological markers of progression from mild cognitive impairment to Alzheimer's disease, and that hippocampal atrophy and whole brain atrophy have strong evidence as structural markers. The findings are about tracking disease progression and do not report on treating, curing, or preventing Alzheimer's disease.
Study details
- Study designcross-sectional
- Evidence strengthLow
How this study scored 52/100
Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Alzheimer's disease : JAD) |
| Journal's citation record | 2 / 4 | Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2011 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 142 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 8.4 citations a year over 17 year(s) since 2011 |
| Impact for its field and year | 3 / 6 | Cited 7.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 2 / 4 | Cited 16 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Giovanni Battista Frisoni: h-index 120 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Centre National de la Recherche Scientifique: institution h-index 2,511 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 16 institution(s) in 6 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 21971460) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 47.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.
Related studies in Mild cognitive impairment from nearby years
Also tagged “machine”
834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.